Supreme Court Struggles Over What Constitutes A ‘Fact’ In Copaxone Case
This article was originally published in The Pink Sheet Daily
Executive Summary
Justice Breyer seems to side with Teva’s position that Federal Circuit should have deferred to district court’s finding on meaning of patent term central to Copaxone’s manufacturing process, but other justices appear skeptical.